Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Status:
RECRUITING
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Phase:
PHASE1
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
Hamilton Academic Health Sciences Organization St. Joseph's Health Care London